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Abstract The aim of this study was to investigate the e¡ects of various pretreatment clinical and laboratory charac-
teristics on the survival of patientswith di¡usemalignant pleuralmesothelioma (DMPM).One hundredhistopathologically
con¢rmed DMPM patients were evaluated. Fifty-nine were treated with chemoimmunotherapy, while 41who had re-
fused chemoimmunotherapy received supportive therapy alone.The following pretreatment characteristicswere eval-
uated in both univariate and multivariate Cox regression analyses: age, gender, Karnofsky performance score (KPS),
histology, asbestos exposure, presence ofchestpain, dyspnoea, weight loss, symptomduration, smokinghistory, disease
location, plateletcount, haemoglobin, white bloodcell (WBC) count, serumlactate dehydrogenase (LDH) andextentof
disease (stage).Univariate analysis showed that patients with age 75 years, male gender, smoking history, advanced
stages above stage I disease,KPS 570,WBC count 8450 and LDH level 500 IUl71 have a worse prognosis.With
multivariate Cox regression analyses, age 75 years, advanced stages above stage I disease,KPS570 and LDH level
500 IUl71were foundtobeindicatorsof apoorerprognosis.Inconclusion, inour studyeachof lowperformancestatus,
older age, advanced stage disease, high LDHlevel andprognosiswere found to berelated.c 2001Harcourt Publishers Ltd
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Di¡use malignant pleural mesothelioma (DMPM) is a
highly lethal neoplasm (1,2). It has continued to be an
important health problem for communities that have
occupational or environmental asbestos exposure (3^5).
The incidence of this aggressive tumour is still increasing
and is expected to go on doing so (6^8). In most
published series of patients, the median survival for this
disease is reported to be about1year (9^12). Although it
is claimed that multi-modality regimens slightly prolong
survival for relatively few patients in whom it is possible
to perform radical surgery (13,14), most patients have
unresectable disease at presentation and systemic
therapy has been the only treatment option for them.
However, to date, the overall response rate is low and
the median survival time is not long enough for
chemotherapy schedules. Well de¢ned studies indicateReceived16 January 2001and accepted in revised form 21June 2001.
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resistant, and some chemotherapeutics are moderately
e¡ective for responsive patients (15^18).
Studies are largely contradictory about prognostic
factors for DMPM which would be helpful in planning
appropriate treatment for these patients and evaluating
the e¡ects of treatment (19^21).Therefore, future inves-
tigations should be aimed at determining which patients
will be responsive and identifying useful prognostic
factors.
Our clinic is a department of the Medical Faculty of
Osmangazi University in Eskisehir, Turkey.The Eskisehir
district is located in central Anatolia.Many patients with
DMPM or other asbestos-related chest diseases are
admitted to our clinic in each year. Although there is no
occupational asbestos exposure in the Eskisehir district,
environmental asbestos exposure due to the use of
asbestos-contaminated white-soil was very widespread
in our rural region until the1980s (7).
In this study we aimed to investigate the e¡ects of
variouspretreatmentclinical and laboratorycharacteris-
tics on the survival of patients with DMPM.
TABLE 1. Characteristics of the patients
Patients characteristics
Patient number 100
Mean age (range) 57?0 (26^90) years
Male: female 49 : 51
Asbestos exposure 81 (81%)
Mean asbestos exposure duration
(range)
26?7 (0^80) years
Stage
I 31 (31%)
II 20 (20%)
III 32 (32%)
IV 17 (17%)
Histopathologic subtype
Epithelial 48 (48%)
Mixed 18 (18%)
Sarcomatous 11 (11%)
Unidenti¢ed 23 (23%)
Mean Karnofskyperformance status
(range)
70?5 (50^90)
Smokinghistory 42 (42%)
Men smoking 38/49 (78%)
Women smoking 4/51 (8%)
Mean symptomduration (range) 5?0 (0?3^72)months
Symptoms atdiagnosis
Weight loss 53 (53%)
Chest pain 78 (78%)
Dyspnoea 80 (80%)
Numberof patients treatedwith
chemotherapy
59
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Patients
One hundred consecutive patients with histologically-
proven DMPM, from January 1991 to December 1999,
were evaluated in this study.Histopathological examina-
tion of biopsy samples from all patients has been per-
formed in the Pathology Department of our Faculty.Of
the samples, 29 were also examined by Dr A.R. Gibbs
from Llandough Hospital in U.K. Samples were stained
with haematoxylin^ eosin, alcian blue and mucicarmine
histochemical stain. Immunohistological con¢rmation of
carcinoembryonic antigen and Leu-M1was obtained for
these 29 patients, and carcinoembryonic antigen, vimen-
tin and keratin in the others. After the histopathological
diagnosis, all patients were staged according to the
International Union Against Cancer staging system
by using thoracic, abdominal and brain computer
tomographic scans, bone scanwithTC99 and other related
tests (22,23).
Of the patients, 59 were put on a chemoimmuno-
therapy programme consisting of cisplatin, mitomycin C
and recombinant interferon-a 2a or carboplatin, mito-
mycin C and ifosfamid, while 41 were given supportive
therapy alone (24).
The following pretreatment characteristics were evalu-
ated for prognostic importance: age (75 years or 575
years), gender, Karnofsky performance score (KPS) (70
or570), asbestos exposure (yes or no), presence of chest
pain, presence of dyspnoea, weight loss (more than 5%),
symptom duration (3 months or 53), smoking history,
primary location of disease (right, left), platelet count
(4400 000ml71 or 400 000), haemoglobin, white blood
cell (WBC) count, serum lactate dehydrogenase (LDH),
extent of disease (stage), histopathologic subtype. Histo-
pathologic subtype could notbe determined in 23patients,
whowere excluded in the analysis of theprognostic impor-
tance of histopathology. Since laboratorynormalrangewas
not suitable for LDH,we chose a level of over 500 IUl71as
the cut-o¡ level, to be consistent with published literature
(20). Since the accepted norms for WBC and haemoglobin
levels vary, we ¢rstly determined the median values for
each in the study group and used those as cut-o¡ levels for
prognostic evaluation (8450ml71for WBC and12?65gdl71
for haemoglobin (21).
Statistical analysis
Duration of survival and median and mean event times,
with 95% con¢dence interval (CI), were estimated ac-
cording to the Kaplan^Meier method. The duration of
survival was de¢ned as the period between the time of
diagnosis and the time of death, or last contact if the pa-
tient had not died at the time of analysis. Comparisons
for all survival were made using two-tailed log-rank
tests. The proportional hazards regression model withstrati¢cation for the clinical trial was used for both
univariate and multivariate analyses.Univariate analyses
examined the prognostic importance of all factors men-
tioned above. The cox proportional hazards model was
used to examine variables. A two-sided test was used at
0?05 levelof signi¢cance. A step-down/step-wisevariable
selection procedure was used to ¢t the multivariate
model.Onlyparameterswhich hadP-values0?10 inuni-
variate analysis were taken in the ¢nal model for multi-
variate analysis (19).
The importance of a prognostic factor was assessed
by the P-value of the Wald w2 statistic, the relative risk
(RR; risk inpatients in a given category as comparedwith
the reference one), and its 95% CI. Statistical analyses
were performedusing SPSS statistical software.
RESULTS
The patients’ characteristics are given inTable1.Of the100
patients, 81 had environmental asbestos exposure.Of the
total, six patientswere alive at the time of the analysis.
The overall median survival time of the patients was
8?0+0?9 months. The median survival time was 9?0
TABLE 2. Univariate analysis of patientcharacteristics in£uencing survival
Variable O/N* % Survival{ 95% CI P
Age (years)
575 86/92 0.93 8.50 5?37^11?63 0?02
75 8/8 1?00 2?00 0?00^4?13
Sex
Male 46/49 0?94 6?70 5?56^7?84 0?09
Female 48/51 0?94 11?50 7?62^15?38
Asbestos exposure
Absent 17/19 0?89 6?70 4?99^8?41 0?92
Present 77/81 0?95 8?50 4?97^12?03
Smoking
Ever 39/42 0?95 6?30 5?03^7?57 0?10
Never 55/58 0?93 11?0 7?27^14?73
Stage
I 27/31 0?87 16?0 8?90^23?10
II 20/20 1?00 6?30 4?11^8?49 0?00
III 30/32 0?94 6?30 4?82^7?78
IV 17/17 1?00 5?00 3?66^6?34
Histopathological type
Epithelial 45/48 0?94 9?00 4?83^13?17
Mixed 18/18 1?00 6?70 2?54^10?86 0?16
Sarcomatous 11/11 1?00 7?00 2?31^11?69
Karnofsky
70 65/70 0?93 11?00 7?42^14?58 0?0002
570 29/30 0?97 5?00 3?66^6?34
Primary site of tumour
Right 57/59 0?97 8?00 6?07^9?93 0?53
Left 37/41 0?90 11?00 5?37^16?63
*Observed deathnumber/totalpatientnumber.
{Median survival (months).
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8?0 months for the patients had supportive care alone;
there was no signi¢gance between these groups (log
rank=1?28; P=0?26). Univariate analyses of patient
characteristics and various aspects in£uencing survival
at presentation are shown inTables 2 and 3.
Age75 years, male gender, smoking, advanced stage
above stage I disease, KPS570,WBC count 8450 and
LDH level500 IUl71, with P-values0?05 in univariate
analysis taken in the ¢nal model for multivariate analysis
(Table 4).
In the multivariate analysis model, age 75 years, ad-
vanced stage above stage I disease, KPS570 and LDH
level500 IUl71were found to be indicators of apoorer
prognosis.
The survival curves of the patients for age, stage, KPS
and LDH values of the patients are shown in Figs 1^4,
respectively.
DISCUSSION
In the present study, we investigated the e¡ects of
various pretreatment characteristics on the survival ofpatients with DMPM.Most of our patients had environ-
mental asbestos exposure due to the use of asbestos-
contaminated white-soil (7).There are some di¡erences
not only in terms of the nature of the exposurebetween
those with environmental and those with occupational
exposure but also in the individual characteristics of the
patients. The male to female ratio of our patients was
nearly 1:1. This ratio re£ects the environmental expo-
sure to asbestos in rural areas, as women and men live
in the same rural environment and conditions. Mean
lengths of exposure were the same for both sexes (7).
On the other hand, themean age of our patients was 57
years. In another study fromTurkey, the environmental
asbestos exposure series for Selc° uk, the average age
was 50 years, with a quarter of the patients below 40
years of age (4).Themean ages of thepatients are around
60^65 years in patients with occupational exposure
(25,26).The younger mean age in our series may be due
to the beginning of asbestos exposure at birth.
DMPM arises from the pleura and/or peritoneum,
with a poor prognosis, and until recently there has been
no treatment schedule to slow its course (3,5,9^
12,14,20,27,28). Most patients with DMPM have had
TABLE 3. Univariate analysis of other variouspatientcharacteristics in£uencing survival
Variable O/N* % Survival{ 95% CI P
Chest pain
Ever 73/78 0?94 8?00 6?02^9?98 0?87
Never 21/22 0?95 8?50 3?67^13?33
Dyspnoea
Ever 76/80 0?95 8?00 6?17^9?83 0?52
Never 18/20 0?90 8?50 4?12^12?88
Weight loss
Ever 50/53 0?94 8?0 6?28^9?72 0?2-
8
Never 44/47 0?94 10 5?20^
14?80
Plateletcount
 400 000 67/72 0?93 8?50 5?48^11?52 0?44
4400 000 27/28 0?96 6?00 3?41^8?59
WBCcount
58450 45/49 0?92 11?00 6?43^15?57 0?07
8450 49/51 0?96 7?00 5?06^8?94
Haemoglobin
512?65 48/49 0?98 9?00 4?60^13?40 0?73
12?65 46/51 0?90 7?00 4?50^9?50
LDHlevel500 IUl71
Yes 22/22 1?00 3?50 0?00^7?41 0?02
832 RESPIRATORYMEDICINEunresectable disease at presentation and systemic
therapy has been the only treatment option for them
(13^17,20,22^38). Chemotherapy regimen cannot be
considered as the standard of DMPM treatment
(9,16,17,20^22,27,31,32). Although to date the overall
response rate has been low and themedian survival time
is not long enough to justify chemotherapy schedules,
some studies indicate that mesothelioma may not be
totally chemotherapy-resistant and that some
chemotherapeutics are moderately e¡ective and toler-
able, especially for responsive patients (16,20,24,27,32).
In view of this, future investigations should be aimed at
determining which patientswill be responsive and which
patients will have a chance of good prognosis.
Identi¢cation of the patient’s prognostic characteris-
tics may be useful in planning future studies and under-
standing and interpreting their results. Various patient
characteristics have been examined in a number of
studies to determinewhether theyhave anypotential ef-
fect on the prognosis of patients with DMPM (20). In
most of these studies, cases of stage 1 disease with
epithelial histology and good performance status were
commonly presented to have a good prognosis. How-
ever, in recent studies, additional parameters such
as older age (20,33), LDH 500 IUl71, platelets
4400 000ml71, chest pain (20), male gender (21)and high WBC count (21) were reported to have a
signi¢cantly poorer prognosis.
Any regression model is based on a particular,
assumed relationship between the dependent variable
and the explanatory covariates. It is important to exam-
ine thevalidity of this assumedrelationship.Most regres-
sionmodels allow themodel assumption to be examined.
In the current study, we determinedbyusingunivariate
analyses, that age 75, male gender, smoking, advanced
stages above stage I disease, KPS 570, WBC count
48450 and LDH level 500 IUl71 are linked to the
worse prognosis. In multivariate Cox regression
analyses, age 75, advanced stages above stage I disease,
KPS570 andLDHlevel500 IUl71were determinedas
indicators of a poorer prognosis independently.
The factors related to a poor prognosis in malignant
mesothelioma put forward in most publications to date
are the following: lowperformance status, advanced age,
advanced stage of disease. In one study, a mixed histo-
pathology was reported to have a worse survey than
others (19).However, in another study it was found that
mesotheliomas with mixed type histology were asso-
ciated with longer survival time than the sarcomatous
types (2). In three other studies, it was determined
that the prognosis of epithelial type mesotheliomas was
better than the others (1,20,34). Authors in that study
TABLE 4. Multivariate stepwisemodel
Varaiable Riskratio 95% CI P
Age (years)
575 1
75 2?513 1?173^5?384 0?018
Stage
I 1
II,III,IV 1?936 1?145^3?273 0?014
Gender
Female 1
Male 1?476 0?808^2?695 0?205
Karnofsky score
70 1
570 2?587 1?490^4?492 0?001
WBCcount
58450 1
8450 1?380 0?880^2?162 0?161
LDHlevel500 IUl71
No 1
Yes 1?703 1?025^2?830 0?040
Smoking
Never 1
Ever 1?402 0?779^2?522 0?260
FIG. 1. Survival curves for age of patients. Age575 years (ö)
and age75 years (- - - - -).
FIG. 2. Survival curves for stages of patients. Stage I (ö) and
stages II,III, IV (- - - -).
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of sarcomatous type cases in their study or to interna-
tional di¡erences in subtype classi¢cation (19). In our
study, patients with the epithelial type had a 9-month
median survival, sarcomatous 7 months, and mixed 6?7
months. There were no signi¢cant di¡erences between
the three types of tumour.
In our study, as in themajority of other studies, a rela-
tion was found between each of older age, performancestatus, advanced stages above stage I disease and LDH
level 500 IUl71, and prognosis both in univariate and
multivariate analyses. An overview of the relevant publi-
cations provides grounds for making a generalization
concerning these relations.
We determined a relation between male gender,
smokinghistory andpoor prognosis inunivariate analysis
but notmultivariate. Possibly, since in our patients smok-
ing rate was much higher in males than females (78% vs.
FIG. 3. Survival curves for Karnoskyperformance score of pa-
tients.Karnosky70 (ö) and Karnofsky570 (- - - - - -).
FIG. 4. Survival curves for LDH values of patients. LDH
5500 IUl71 (ö) and LDH4500 IUl71 (- - - - -).
834 RESPIRATORYMEDICINE8%), smoking-related co-diseases such as chronic
obstructive lung disease (COPD) and atherosclerotic
heartdiseasemighthave ane¡ecton the survival of smo-
kers and therefore on the the survival ofmale patients.
There is insu⁄cientknowledge to date aboutwhether
or not there is a relationship between patients’ respon-
siveness to chemotherapy and the prognostic character-
istics so far studied and determined. For this reason,
as we have stated above, in order to evaluate such an
important point as the ability to determine beforehand
which patients will respond to chemotherapy there is
an urgent need for studies investigating prognosis
and the related parameters, as well as the relations
between these parameters and responsiveness, in
both patients responsive and non-responsive to chemo-
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